HMGB1
米诺环素
缺血
再灌注损伤
医学
细胞凋亡
乳酸脱氢酶
心肌保护
肌酸激酶
药理学
膜联蛋白
心肌细胞
麻醉
内科学
化学
炎症
生物化学
酶
抗生素
作者
Xiaorong Hu,Xin Zhou,Bo He,Cheng Xu,Wu Liu,Bo Cui,Wen Hu,Zhibing Lu,Hong Jiang
标识
DOI:10.1016/j.ejphar.2010.03.059
摘要
Minocycline has been shown to protect against myocardial ischemia and reperfusion injury. However, the mechanism remains unclear. This study was to investigate the role of high mobility group box 1 protein (HMGB1) in the cardioprotection of minocycline during myocardial ischemia and reperfusion in rats. Anesthetized male rats were once treated with minocycline (45 mg/kg, i.p.) 1h before ischemia, and then subjected to ischemia for 30 min followed by reperfusion for 4h. The lactate dehydrogenase (LDH), creatine kinase (CK) and infarct size were measured and the myocardial tissue apoptosis was assessed by TUNNEL assay. Neonatal rat ventricular myocytes were prepared and then cultured with recombinant HMGB1. Cell apoptosis was measured using an annexin V-FITC apoptosis detection kit. HMGB1 expression was assessed by immunoblotting. After 4h of reperfusion, minocycline could significantly decrease the infarct size, myocardium apoptosis and the levels of LDH and CK (all P<0.05). Meanwhile, minocycline could also significantly inhibit the HMGB1 expression during myocardial ischemia and reperfusion compared to that in ischemia and reperfusion group (P<0.05). In vitro, HMGB1 could significantly decrease the cell viability and promote the apoptosis of neonatal myocytes in a dose-dependent manner. The present study suggested that minocycline could protect against myocardial ischemia and reperfusion injury by inhibiting HMGB1 expression.
科研通智能强力驱动
Strongly Powered by AbleSci AI